HCR 561 Module 5 Essay

/in /by

HCR 561 Module 5 Essay

Inclusion of Mentally Incapacitated Individuals in Research

Mentally incapacitated individuals are a vulnerable group in research. They include individuals with dementia, psychiatric conditions, impairments in cognition, or head trauma. These conditions have the potential to prevent their understanding of study procedures or informed consent. As a result, they become susceptible to exploitation or misrepresentation when participating in research.

Justification for Inclusion

Inclusion of this population group in research is ethically and legally sound, despite the risks that this inclusion creates. The Belmont Report outlines three principles: respect for persons, beneficence, and justice. These principles support the inclusion of vulnerable groups when additional protections are in place (Ogg, 2005). Justice, in particular, highlights the need to ensure that all populations have equal access to the benefits of research.

Federal regulation 45 CFR 46 Subpart A (Common Rule) creates the obligation that researchers should exercise caution when recruiting persons who have an impaired consent capacity. Subpart C grants defined protections to vulnerable populations, particularly in cases where the research poses greater than minimal risk (Protections, 2025). The Declaration of Helsinki also demands that the subjects who do not comprehend the risk of the research give informed consent only when the risk is minimal and the research is consequential.

Mentally incapacitated individuals should also be included, particularly due to the increasing cases of dementia and other cognitive disorders (Shepherd, 2022, p. 2). Leaving them out limits and undermines science and denies them the opportunity to enjoy, perhaps, life-saving treatments.

Risk of Exploitation

Mentally incapacitated individuals can be abused in a number of ways. First, they can be recruited without the actual knowledge of the study. Second, they can take part in high-risk studies without protection. Third, their proxies may make decisions based on personal opinions, not the participant’s known wishes (Shepherd, 2022, p. 3).

Research indicates that even competent adults have been misinformed about several important issues regarding informed consent. These are risks, randomisation, and the distinction between treatment and research (pietrzykowski & smilowska, 2021, p. 3). These issues are magnified among groups that have poor cognition.

Informed Consent Challenges

The simplest ethical research requirement is informed consent. However, legally, there is a possibility that mentally incapacitated persons might not have the legal capacity to consent. In such a case, a legally authorized representative (LAR) or proxy is required to make the decision on their behalf.

Federal regulations under 45 CFR 46.116 and 46.117 require that consent documents be understandable and voluntarily signed. However, according to Shepherd (2022, pp. 4 5), numerous proxies lack guidance and are overwhelmed by the responsibility of these decisions. They might not easily determine the preferences of the individual, particularly where he/she did not clearly discuss his/her preferences.

To support ethical consent:

  1. The use of simple language and images should guide researchers.
  2. Seek assent from the participant where possible.
  3. Reaffirm consent at various phases of the study
  4. Train proxies regarding their duties and the rights of an individual (Shepherd, 2022, p. 6).

Privacy and Confidentiality

It is also important to maintain confidentiality. Those with mental incapacity might lack an understanding of the usage of their data. According to Pietrzykowski and Smilowska (2021, p. 4), privacy definitions in consent forms are commonly misinterpreted, even by healthy adults.

To protect this group:

  1. Data rights and usage should be clearly stated in the consent forms.
  2. De-identify participant data
  3. Restrict access to data to key personnel.
  4. Use secure, encrypted systems.

HIPAA is also applicable when research utilizes protected health information. By adhering to the following regulations, researchers can avoid privacy violations.

Conclusion

Mentally incapacitated people are in the most vulnerable positions as research participants. However, their inclusion is ethically necessary. Their involvement can be fair and productive with the appropriate protection. Researchers can safeguard this population using federal laws like 45 CFR 46, ethical considerations of the Belmont Report, and the current best practices. Respect, dignity, and justice should lie at the core of any study involving vulnerable populations.

References

Ogg, G. (2005). A practical guide to quality management in clinical trial research. CRC Press.

Pietrzykowski, T., & Smilowska, K. (2021). The reality of informed consent: empirical studies on patient comprehension—systematic review. Trials, 22, 1-8.

Protections, O. F. H. R. (2025, February 12). 45 CFR 46. HHS.gov. https://www.hhs.gov/ohrp/regulations-and-policy/regulations/45-cfr-46/

Shepherd, V. (2022). (Re)Conceptualising ‘good’ proxy decision-making for research: the implications for proxy consent decision quality. BMC Medical Ethics, 23(1). https://doi.org/10.1186/s12910-022-00809-5

HCR 561 Module 5 Essay

CLICK HERE TO ORDER A PLAGIARISM-FREE PAPER

HCR 553 Module 5 Quality in Clinical Trials

/in /by

HCR 553 Module 5 Quality in Clinical Trials

Introduction

Yes! The use of digital pills in clinical trials is a promising innovation. The antipsychotic drug aripiprazole, in combination with an ingestible sensor developed by Proteus Health and Otsuka, illustrates how technology can help solve long-term issues in research. Ensuring that the participants follow the prescription of their medications is one of the main issues of clinical trials. This has an impact on the reliability of data and the reports of drug effectiveness. The digital pills offer a method of real-time ingestion monitoring, enhancing accuracy and the quality of the overall trial.

Clinical Trial Benefits

The pills are particularly applicable in those tests in which compliance is paramount, like the ones on psychiatric disorders. As an illustration, schizophrenia patients tend to fall out of their medication schedules. In this context, non-compliance can be detected by the use of a sensor to monitor medication intake among individuals, which can aid researchers to detect non-compliance at an early stage (Satyamitra et al., 2022). This enables prompt interventions, which potentially enhances participant results and retention levels. The tool complies with the FDA regulations: 21 CFR Part 312, which focuses on proper data collection when investigating drugs.

The digital pills similarly meet 21 CFR Part 11 of the FDA, which promotes the application of electronic records in research. This implies that data gathered through digital ingestion may be stored, checked, and secured under controlled systems (Ogg, 2005). By the use of these records, researchers will not be required to depend on self-reported information, which tends to be erroneous. Digital pills can provide objective data that may contribute to more accurate trial results.

Ethical Considerations

Nevertheless, the ethical issues of these instruments also exist. Informed consent is made more complicated. The participants have to be aware of the fact that they are not only taking a drug but are also under observation. The principle of respect for persons described in the Belmont Report entails informing participants of the nature and purpose of the research (Ogg, 2005). If participants are not told how their data will be used or if they feel coerced, then ethical violations may occur.

Privacy and Autonomy

Privacy is another big issue. Such ingestible sensors should provide information that is protected by systemic safety standards like the Health Insurance Portability and Accountability Act (HIPAA). In the event of creating access to or sharing the information without proper protection, there is a possibility that confidentiality may be breached (Satyamitra et al., 2022). In sensitive experiments, they may not feel relaxed that their consumption of medication is being monitored. This becomes particularly serious when looking into psychiatric patients who might already feel vulnerable.

Digital pill usage is also a question of autonomy. The participants should be the ones to agree to this method of tracking without being locked out of the trial. The subjects have to be, according to the standards of Good Clinical Practice (GCP), treated with dignity and freedom of choice (Meyer, 2020). If digital pills are made mandatory, this may reduce participation or lead to forced consent.

Justice and Equity

The codes, like the Declaration of Helsinki, remind us that in all research, the most important thing is the welfare of the study subject. The use of monitoring equipment should not be transformed into surveillance and punishment. Instead, they would need to be utilized to enforce the health of the individual and protect the integrity of the testing. Moreover, the researchers ought not to be biased in selecting subjects. Once this is available only to particular populations who can either afford or access the technology, the principle of justice associated with the Common Rule (45 CFR 46) is violated (Meyer, 2020). All participants should receive a level playing field to benefit equally without discrimination based on technology access.

Conclusion

Ultimately, the digital pills can enhance data quality and compliance in clinical trials significantly. They give accurate and real-time information that cannot be received through traditional means. However, the success of such innovation depends on how it is carried out. The researchers need to balance the cost and ethical responsibility. Participants are to be informed fully, their information must be secured, and their independence must be respected. With the necessary safeguards, digital pills can form part of the future of clinical research.

References

Meyer, M. N. (2020). There Oughta Be a Law: When Does(n’t) the U.S. Common Rule Apply? The Journal of Law Medicine & Ethics, 48(S1), 60–73. https://doi.org/10.1177/1073110520917030

Ogg, G. (2005). A practical guide to quality management in clinical trial research. CRC

Press.

Satyamitra, M. M., Perez-Horta, Z., DiCarlo, A. L., Cassatt, D. R., Rios, C. I., Price, P. W., & Taliaferro, L. P. (2022). NIH Policies and Regulatory Pathways to U.S. FDA licensure: Strategies to Inform Advancement of Radiation Medical Countermeasures and Biodosimetry Devices. Radiation Research, 197(5). https://doi.org/10.1667/rade-21-00198.1

CLICK HERE TO ORDER A PLAGIARISM-FREE PAPER

 

 

 

HCR 553 Module 5 Quality in Clinical Trials

HCR 553 Module 5 Six Sigma

/in /by

HCR 553 Module 5 Six Sigma

Article Summary

Kwak and Anbari’s (2006) article, “Benefits, Obstacles, and Future of Six Sigma Approach”, does a thorough analysis of the six-sigma methodology as a data-driven strategy of a quality improvement system in an organizational context, such as in healthcare. Six Sigma originated in the manufacturing sector as a quality improvement methodology. It aims to achieve near-perfect performance by limiting defects to fewer than 3.4 per million opportunities through rigorous process evaluation and control.

The authors differentiate between the statistical and business perspectives of Six Sigma and highlight the transformation of this method into a system of project management and quality enhancement. The DMAIC (Define, Measure, Analyze, Improve, Control) approach enables organizations to reduce the variation and performance gaps through a systematic approach of reduction, thereby ensuring measurable financial and increased customer satisfaction. Key enablers of successful implementation, including management commitment, cultural adaptation, and training, are also identified in the article, as well as key barriers, especially strategic alignment and organizational culture.

The authors use the examples of the medical sector application (although it is not a primary case study), where Six Sigma was applied successfully at MD Anderson Cancer Center to cut time spent preparing patients and to increase diagnostic volume. This brings out the applicability of the method in both clinical and service-based settings.

Application of the Six Sigma Approach (Six Steps)

The article aligns closely with the six-step Six Sigma approach used in healthcare. Below is how each step was reflected in the article:

  1. Define the Goal and Scope

Kwak and Anbari (2006) reiterate the importance of clearly defined goals in successful Six Sigma projects, including goals being coupled with customer needs or business strategies. As an example, GE set objectives to reduce railcar repair turnaround times, whereas MD Anderson worked on decreasing delays in preparing CT scans (strategically to enhance quality and efficiency) (Kwak & Anbari, 2006).

  1. Create a Performance Baseline

It is necessary to set control limits and performance benchmarks. According to the authors, companies such as Motorola and Bank of America went as far as taking baseline measurements of the defect rates and delivery service rates. Examples of baseline measures in the field of healthcare may involve normal wait times or patient satisfaction ratings prior to intervention.

  1. Monitor Performance and Collect Data

The article focuses on systematic data collection. Real-time information is recorded with the use of dashboards, surveys, and statistical process control charts that enable continuous monitoring (Kwak & Anbari, 2006). At MD Anderson, radiology workflow data was utilized to track delays in services and usage of equipment.

  1. Solve the Problem by Removing Root Causes

A solid principle of Six Sigma is root cause analysis. As Kwak and Anbari (2006) show, organisations such as AstraZeneca and DuPont deployed advanced forms of statistics to detect inefficiencies in their operations. Within the healthcare industry, this may include determining process bottlenecks within patient scheduling or claims processing.

  1. Implement Procedures to Remove Root Causes

Creative problem solving is then used to implement solutions. As an example, GE renovated shop processes, and MD Anderson restructured the CT workflow. These troubleshooting measures hit the mark when it came to the causes of variation and delay.

  1. Evaluate System Performance Post-Implementation

Testing is very crucial. The article refers to such huge gains as a 62% reduction in turnaround time at GE and financial savings of over 2 billion dollars achieved through Six Sigma (Kwak & Anbari, 2006). In healthcare, MD Anderson experienced a reduction in prepping time to less than 5 minutes, compared to 45 minutes in most instances, all a testimony to the effectiveness of Six Sigma.

Success Evaluation

Six Sigma, as presented in the article, has had very impressive success when well executed through effective leadership, training, and cultural fit. The authors mention companies such as GE, Honeywell, and Johnson & Johnson that obtained meaningful operational and financial outcomes (Kwak & Anbari, 2006). In the medical field, the MD Anderson case shows how clinical services may be improved with a quantified change in the patient flow and resource performance.

Such achievements are the results of a data-driven model and effective project management. The central focus of the article is on both statistical rigor and on measures and metrics driven by customer results means that the results are not theoretical but can be proven in practice.

Such advantages have become possible in pharmaceutical industries as demonstrated by Reddy et al. (2024). Six Sigma allowed AstraZeneca to deal with the issue of variability in the process of tablet coating, which contributed to the consistent product quality and quality compliance. These applications further stabilize the flexibility of Six Sigma to industries other than manufacturing.

Potential Improvements

While Six Sigma is effective, Kwak and Anbari (2006) highlight several challenges that suggest room for refinement:

  1. Training Quality: Using Black Belts and Champions who are not qualified to serve in this position usually sabotages the results of the projects. Higher levels of training and certification are required, and this sentiment is also reflected by Reddy et al. (2024), who saw such obstacles in drug companies.
  2. Cultural Resistance: The issue of change management is very important. Companies should engage in investment in communication strategies to ensure buy-in at every level.
  3. Lean integration: This involves integrating Lean with Six Sigma in order to bolster speed and accuracy. According to Reddy et al. (2024), Lean Six Sigma allowed companies such as GSK to cut the production period to 30 days 120, and this may be an impressive possible hybrid model in healthcare.

Ultimately, no system can be ideal; however, Six Sigma, particularly modified to the organizational culture and combined with Lean, is the most effective instrument of sustainable quality improvement.

References

Kwak, Y. H., & Anbari, F. T. (2006). Benefits, obstacles, and future of six sigma approach. Technovation, 26(5–6), 708–715. https://doi.org/10.1016/j.technovation.2004.10.003

Reddy, A., Nagpal, D., & Saxena, S. (2024). A six sigma approach to pharmaceutical industry- a better insight. Oriental Journal of Chemistry, 40(5), 1415–1425. https://doi.org/10.13005/ojc/400525

HCR 553 Module 5 Six Sigma

CLICK HERE TO ORDER A PLAGIARISM-FREE PAPER

Module 6 HCR 553 Discussion Post

/in /by

Module 6 HCR 553 Discussion Post

As the Quality Manager of our Clinical study site, choosing a compliant and efficient Clinical Trial Management System (CTMS) is a very important task. The CTMS should be able to comply with the regulatory standards of 21 CFR Part 11, which governs the use of electronic records and electronic signatures. The rules are meant to guarantee the integrity of data, the safety of patients, and the transparency of regulation. Failure to comply can result in rejection of trial data, slowing down product approval. In order to evaluate compliance, two important questions that I would pose during the evaluation process with the vendors are:

  1. Does the CTMS have a validated audit trail that automatically records all entries, changes, and deletions with user identification and time stamps?

Rationale:

The system should produce computer-based secure audit trails according to 21 CFR 11.10(e). These must record everything that has been done with regard to creating, modifying, or deleting records. The audit trail should also have the time and date of the action and the user who made it. The importance of this question is that audit trails form a backbone in the issue of data integrity. They enable monitors, sponsors, and regulatory bodies to follow the data entry history. According to Ogg (2005), quality documentation is an essential part of any Quality Assurance (QA) system, as this is the primary source of information that has to be reliable and up-to-date. Audit trails support quality control (QC) by identifying trends or errors early.

  1. Does the CTMS support role-based access control and electronic signatures that meet the requirements of 21 CFR 11.10(d) and 11.100–11.300?

Rationale:

The electronic signatures have to be original, safe, and legally acceptable. Role-based access makes sure that only a person with access to particular records can view or modify them. This mitigates the possibility of unauthorized access or data tampering. Sections 11.100 to 11.300 elaborate on the procedures to be followed by systems to verify the identity of a user and ensure signature integrity (21 CFR Part 11 — Electronic Records; Electronic Signatures, n.d.). The question makes sure that the CTMS safeguards sensitive data and abides by federal legislation. Ogg (2005) notes that sound Quality Management System (QMS) comprises user access, safety, and clear roles and duties.

In conclusion, a Clinical Trial Management System (CTMS) has to be more than just a basic thing. It has to achieve data reliability, security, and compliance. By posing these two specific questions, we will give precedence to systems that comply with FDA regulations and enhance quality clinical research throughout the entire process.

References

21 CFR Part 11 — Electronic records; Electronic signatures. (n.d.). https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-11

Ogg, G. (2005). A practical guide to quality management in clinical trial research. CRC

Press.

Module 6 HCR 553 Discussion Post

CLICK HERE TO ORDER A PLAGIARISM-FREE PAPER

Article Review Module 6 HCR 553

/in /by

Article Review Module 6 HCR 553

Article under Review: https://www.healthline.com/health-news/why-this-fda-approved-drug-for-pre-term-birth-is-being-pulled-from-the-market

  1. Introduction

The Food and Drug Administration (FDA) has a significant role in safeguarding the health of the people. It does this by checking the data in clinical trials in an effort to decide on the safety and efficacy of a drug. Nonetheless, there have been instances of FDA-authorized drugs subsequently being recalled on grounds of adverse effects or ineffectiveness. This paper is a review of Makena, a drug used to prevent preterm birth, in accordance with the article by Pattemore (2023). It looks at why the drug was withdrawn, how clinical trial information was managed, the use of a Data Monitoring Committee (DMC), and whether the matter might have been spotted sooner. The paper also considers what the manufacturer could have done differently regarding FDA regulatory frameworks.

  1. Why Makena Was Withdrawn

Pattemore describes in her 2023 article the removal of Makena, the only FDA-approved medication with the ability to reduce the chance of recurrent preterm delivery. In early 2023, its manufacturer, Covis Pharma, voluntarily stopped manufacturing Makena; at the time of the announcement, the FDA had not yet annulled its approval.

Approval of the drug was initially carried out on a U.S.-based clinical trial in 2003 that had 463 women. This trial demonstrated a decrease in the percentage of preterm births (preterm births less than 37 weeks of gestation) in women who received Makena as opposed to a placebo. Nevertheless, this initial trial used the gestation period as a primary outcome measure and not neonatal morbidity or mortality outcomes.

Further concerns arose following a bigger 2020 foreign study, later dubbed the PROLONG trial. The trial involved more than 1,700 women worldwide and demonstrated the lack of effect on neonatal outcomes in the Makena and the placebo groups. This prompted the Obstetrics, Reproductive, and Urologic Drugs Advisory Committee of the FDA to recommend that the drug be withdrawn. Covis eventually complied with a voluntary withdrawal.

This decision underscores a fundamental problem with the accelerated approval pathway: while it allows for faster access to promising treatments, it also poses risks when early data are later contradicted by comprehensive follow-up studies.

III. Clinical Trial Data Collection and Management

The study involving a surrogate endpoint (gestational age) used as the basis of the approval of Makena was carried out in the early part of 2003. Although this is significant, it is not necessarily a surety of enhanced infant health. The data used consisted of dates of delivery and health of the mother, but no other details on the neonatal outcomes, including respiratory distress, neonatal intensive care, or survival rates. The information was gathered in only one geographical area (the United States), and it was not demographically diverse.

In comparison, the 2020 PROLONG study used wider data collection tools. It involved the description of the neonatal health outcomes as well as the monitoring of the health of mothers in several countries. The study was conducted in adherence to the principles of Good Clinical Practice (GCP), and it had standardized data collection and data management processes. Case report forms (eCRFs) were used to collect data and were continuously monitored per international ethical guidelines.

The FDA permits surrogate endpoints applications following accelerated approval (per 21 CFR 314.500), but these approvals are accompanied by the condition that confirmatory trials demonstrate clinical benefit. In the instance of Makena, the withdrawal call arose since this condition was not fulfilled.

  1. Role of the Data Monitoring Committee (DMC)

Whether or not a Data Monitoring Committee (DMC) was established during the Makena trials has not been explicitly stated in the article. However, it is standard for large international studies like PROLONG to include a DMC. The 2006 guidance document created by the FDA, titled Establishment and Operation of Clinical Trial Data Monitoring Committees, suggests the usage of DMCs in clinical trials with high-risk groups, including pregnant women.

In the absence of any, the DMC probably observed the data and might have reported negative events and efficacy signals. Since the PROLONG trial has been completed and did not find any major safety concerns, one should assume that no significant harms were reported. It was the lack of efficacy and not evidence of harm that led the FDA committee to advise that the drug be withdrawn.

Conversely, the applicability of a Data Monitoring Committee (DMC) in the 2003 trial is less apparent, since the trial was of a smaller magnitude and was consistent with the standards of early-stage drug development at the time. With the development of regulatory expectations, particularly since the passage of the FDA Amendments Act (FDAAA) of 2007, sponsors are subjected to greater responsibilities concerning the operation and monitoring of trials.

  1. Could the Issues Have Been Detected Earlier?

Yes. The issues would have been discovered during the initial trial stages. The initial study back in 2003 was small and selective. It measured the delay of birth but not an improvement in subsequent infant health. Gestational age alone was inadequate just because there was no direct relationship between gestational age and neonatal health.

The FDA process of accelerated approval, which is defined in 21 CFR Part 314 Subpart H and enabled by a statutory basis at 21 U.S.C. 356(c), enables early approval based on surrogate endpoints (21 U.S. Code § 355 – New Drugs, n.d.). Nevertheless, post-marketing confirmatory studies should be carried out by sponsors to demonstrate real clinical benefit. In this case, the confirmatory study came nearly a decade after approval, allowing Makena to remain on the market despite its unproven benefit.

Such a scenario shows the weaknesses of accelerated approval once the surrogate endpoints lack validation, or confirmation trials take time. The FDAAA of 2007 gave the FDA the power to request timely post-mark studies and remove products when they should (Research, 2024). The long-term availability of Makena, even when not of benefit, casts doubt on the enforcement of the requirements.

  1. What Could the Sponsor Have Done Differently?

Several actions could have improved the handling of Makena’s development and post-market oversight:

  1. Stronger Trial Design from the Start: The sponsor should have designed a larger and more diversified placebo-derived trial initially. The greater concordance of the study with FDA expectations of meaningful clinical benefit could have been achieved by including neonatal outcomes as primary endpoints (Research, 2024).
  2. Proactive Engagement with the FDA: The manufacturer should have collaborated more closely with the FDA to discuss initial reservations, determine potential subgroups who could experience benefit, or redesign the drug to be a more effective tool (Ogg, 2005).
  3. Timely Post-Marketing Trials: The sponsor was under the regulatory mandate to perform confirmatory trials as soon as possible after receiving accelerated approval. The time it took to complete the PROLONG trial undermined the system of regulatory reviews and public confidence.

VII. Conclusion 

The recall of Makena provides a valuable case study of drug approval, post-marketing surveillance, and risk management of health in the population. The drug was approved on the basis of small amounts of evidence, but did not demonstrate benefit in a larger and more rigorous trial. The fact that such pitfalls went unnoticed before indicates larger problems with the design of trials, the responsibilities of sponsors, and regulation. The case also demonstrates that there should be a change in the observance of confirmatory trial schedules and risk communication by the FDA. Sponsors, policymakers, and healthcare providers need to collaborate in order to make sure that accelerated approvals in the future will also be evidence-based and well-overseen after approval.

References

21 U.S. Code § 355 – New drugs. (n.d.). LII / Legal Information Institute. https://www.law.cornell.edu/uscode/text/21/355

Ogg, G. (2005). A practical guide to quality management in clinical trial research. CRC

Press.

Pattemore, C. (2023, March 13). Why This FDA-Approved Drug for Pre-Term Birth is being Pulled from the Market. Healthline. https://www.healthline.com/health-news/why-this-fda-approved-drug-for-pre-term-birth-is-being-pulled-from-the-market

Research, C. F. D. E. A. (2024, December 24). Accelerated Approval Program. U.S. Food And Drug Administration. https://www.fda.gov/drugs/information-healthcare-professionals-drugs/accelerated-approval-program

CLICK HERE TO ORDER A PLAGIARISM-FREE PAPER

Article Review Module 6 HCR 553

HCR 576: AI and the Future of Custom-Made Proteins in Drug Development

/in /by

HCR 576: AI and the Future of Custom-Made Proteins in Drug Development

Medical science is undergoing a powerful transformation with artificial intelligence (AI) that allows for the design of custom-designed proteins, including constrained peptides, which are highly stable and potent with versatile properties that make them ideal in medical applications (Mak et al., 2024). This method can accelerate and streamline drug discovery, traditionally a slow and expensive process, by exploring enormous chemical spaces to find promising protein structures with desirable properties. For example, peptide design software now enables researchers to design completely new proteins de novo, which could be used as drugs neutralizing viruses or to inhibit the growth of cancer cells (Mak et al., 2024). This combination of AI and protein design is representative of ideas introduced in Chapter 1 of the textbook that focuses on the increasing influence of biotechnology and computational power in contemporary healthcare developments.

Even though the amount of potential interest in AI-driven custom protein development is astronomical, ethical aspects are paramount. The case study presented in chapter 2 of the textbook identifies the value of striking a balance between innovation, public trust, and safety, especially when emerging technologies have an impact on human health (Bahl, n.d.). The potential safety issues, undesirable side effects, and ethical considerations regarding affordable access to such proteins became a concern when using AI to design proteins. For instance, constrained peptides may be durable enough to be taken as pills, making them more accessible than injectable biologics. Nevertheless, when the companies that produce medications are profit-driven, patients who live in low-income areas will not receive the same benefits as patients in other locations (Bahl, n.d.). Also, the use of algorithms brings up transparency and responsibility challenges; what happens when a protein created by an AI causes unanticipated harm? These ethical issues have to be monitored well, and good regulatory measures put in place to make AI in drug development a responsible process.

I believe that AI should be used in the area of custom protein design, but only under strict ethical regulations. The increased speed and accuracy of AI development can mean decreased time and cost of creating life-saving treatments, which matches the science in the textbook, being seen as a method of enhancing the well-being of the population. However, the same technology should merely supplement rather than substitute human knowledge in medicine (Patel & Shah, 2021). By combining the processing speed of AI and the judgment of humans, researchers may develop safer, more efficient biologics to address critical health issues. I am in favor of what AI can contribute to the field of custom protein design, as long as ethical rules, transparent testing, and suitable accessibility are placed at the forefront of their application.

References

Bahl, C. (n.d.). A new type of medicine, custom-made with tiny proteins [Video]. TED Talks. https://www.ted.com/talks/christopher_bahl_a_new_type_of_medicine_custom_made_with_tiny_proteins

Mak, K. K., Wong, Y. H., & Pichika, M. R. (2024). Artificial intelligence in drug discovery and development. Drug discovery and evaluation: safety and pharmacokinetic assays, 1461-1498.

Patel, V., & Shah, M. (2021). Artificial intelligence and machine learning in drug discovery and development. Intelligent Medicine, 2(3), 134–140. https://doi.org/10.1016/j.imed.2021.10.001

HCR 576: AI and the Future of Custom-Made Proteins in Drug Development

CLICK HERE TO ORDER A PLAGIARISM-FREE PAPER

HCR 576: Drug Development

/in /by

HCR 576: Drug Development

The process of bringing a new drug to the marketplace can be lengthy and complicated, sometimes exceeding a decade and requiring a commitment of great financial risk. As seen by Tamimi and Ellis, only one in a thousand of the synthesized compounds gets to clinical trials, with one out of every ten reaching the market (Tamimi & Ellis, 2009). The clinical trial is done in a controlled manner with the first phase being safety, the second efficacy and dosage, and the third being confirmation on a large scale. This dragging process guarantees that the costs surpass the risks, but it also retards access to potentially life-saving drugs. For instance, in 2023, lecanemab (Leqembi), a medication to treat early Alzheimer’s, reached the market despite passing numerous Phase III trials indicating its safety and efficacy in delaying cognitive loss (Tamimi & Ellis, 2009). This highlights the potential and difficulty of achieving scientific scrupulousness and the pressing necessity of novel treatments.

Another major obstacle is the production of drugs on a pilot scale before full-scale commercialization. To convert laboratory synthesis to commercial scale manufacture, the requirements of stringent regulatory environments and the maintenance of uniformity, quality, and safety must be met (Tamimi & Ellis, 2009). Scaling challenges can stall or even kill promising treatments. It is also very expensive to produce at this stage, and companies have to invest in specialized processes and equipment without guaranteed approval. Patients such as Linnea Olson demonstrate the human consequences of these delays as they can only access experimental ALK inhibitors through clinical trials (TEDx Talks, 2020). When there are regulatory and production bottlenecks, patients who need life-saving treatments are left with few or no options. The FDA’s 2023 approval of Zurzuvae (zuranolone) for postpartum depression illustrates fast but cautious scaling. The company moved quickly through clinical trials and patient access phases to address an urgent need.

Lastly, how quickly drugs are brought to the market is important, particularly with life-threatening illnesses. Clinical trials are not only time-consuming but also costly and emotionally exhausting on the patient, as Olson’s story reveals. She recounted the personal cost of frequent scans, high co-pays, and the uncertainty of trial participation, which serves as a reminder that patients also have a vested interest in the cost of innovation (TEDx Talks, 2020). In response, regulators have established expedited mechanisms, including accelerated approval and breakthrough therapy designation, to bring therapies like Hemgenix (a gene therapy to treat hemophilia B) to the market at an accelerated pace. Although these mechanisms enhance access, they also necessitate a sustained program of post-marketing surveillance to maintain long-term safety. Ultimately, innovation is having to balancing speed, safety, and accessibility so that it can bring real-world difference to the patients in need.

References

Tamimi, N. A., & Ellis, P. (2009). Drug development: from concept to marketing!. Nephron Clinical Practice, 113(3), c125-c131.

TEDx Talks. (2020, January 6). Patient, parent, person, research subject | Linnea Olson | TEDxBeaconStreet [Video]. YouTube. https://www.youtube.com/watch?v=raeLgKHYGBk

HCR 576: Drug Development

CLICK HERE TO ORDER A PLAGIARISM-FREE PAPER

HCR 578: Duty of Care

/in /by

HCR 578: Duty of Care

The principal investigator (PI) has the obvious Duty of Care to the study participants, though this term is not specifically present in the informed consent form. Instead, this duty is implied through several elements of the document.

First, the consent identifies that participants would be monitored through screening, follow-up visits, and safety assessments. This means the principal investigator bears the responsibility for the health and safety of the participant throughout the study (US Department of Health and Human Services). Follow-up visits regularly at 2, 4, 12, and 24 weeks after addressing the issue demonstrate dedication to continued oversight and not abandoning participants after administering treatment.

Second, the section on risks and side effects shows the PI’s responsibilities of warning participants about foreseeable harms. By reporting adverse effects such as discomfort, allergic reactions, or infection, the principal investigator is acknowledging the duty to disclose information that may enable participants to make an informed decision (Yarborough & Sharp, 2009). This openness is included in the ethical requirement of the duty of care, which is to protect participants against unforeseen or preventable dangers.

Third, the consent form contains a part that in the case of complications or injuries that may arise because of the study procedures, the investigator will cover the normal charges of treating the injuries. This goes straight to the role of PI in ensuring the participants are not left without medical care in the event of harm during the trial.

Fourth, confidentiality protections further imply a duty of care. Ensuring that the personal health information is secure and does not get into the wrong hands, the PI is committed to protecting the privacy of the participants (US Department of Health and Human Services). This is central in preserving trust, which has been promoted in the wider studies on research ethics following instances like that of Jesse Gelsinger, where a lack of openness and security of participants damaged public confidence.

Finally, the voluntary participation and withdrawal rights emphasize respect for participant autonomy. Giving the participants an option of exiting the study without any repercussions creates the illusion that the principal investigator is more concerned about their welfare than their research interests (Yarborough & Sharp, 2009). Ethical guidelines, such as those recommended by the FDA and ICH, emphasize that the rights and safety of participants should be of utmost importance compared to study results.

In a nutshell, the informed consent indicates the PI’s obligation of care by monitoring the participants, disclosure of risks, commitment to medical care, confidentiality, and respect of autonomy. Taken together, these aspects indicate that the PI has the duty to act in the best interest of participants during the study.

References

US Department of Health and Human Services. E11 (R1) addendum: clinical investigation of medicinal products in the pediatric population: guidance for industry.

Yarborough, M., & Sharp, R. R. (2009). Public trust and research a decade later: What have we learned since Jesse Gelsinger’s death? Molecular Genetics and Metabolism, 97(1), 4–5. https://doi.org/10.1016/j.ymgme.2009.02.002

HCR 578: Duty of Care

CLICK HERE TO ORDER A PLAGIARISM-FREE PAPER

HCR 578: Children in Research: Legal Protections and Special Considerations

/in /by

HCR 578: Children in Research: Legal Protections and Special Considerations

Introduction

The safety and efficacy of medical products in children require pediatric research. In the past, children would not be included in clinical trials, and off-label use of drugs was common without understanding their effects, dosage, and effectiveness in children. New regulations are being put in place by regulatory bodies such as the U.S. Food and Drug Administration (U.S. FDA) to conduct studies in pediatrics and to institute new safety measures to protect such a vulnerable population. Children present unique ethical, developmental, and physiological challenges that demand careful research planning and execution. Two important legal protections that govern the involvement of children in research, two crucial considerations that researchers should take into account when conducting research with children, and a reflection on the ethical significance of transparency and trust are discussed in this paper.

Legal Issues in Pediatric Research

The 21 CFR Part 50, Subpart D, is the most significant legal requirement that operates in the regulation of pediatric research in the US, as it offers additional protection to children during the clinical trials. One of these rules is 21 CFR 50.51, which allows kids to be involved in research provided that the risks involved are minimal, and informed parental consent and child consent (where applicable) are secured. This principle saves kids from undue abuse and acknowledges their ethical right to join. Notably, it demands that researchers and institutional review boards (IRBs) implement measures so that the risks associated with a study are negligible or no greater than those associated with daily life or ordinary medical procedures (Protection of Human Subjects and Institutional Review Boards, 2022).

The second important rule is 21 CFR 50.52, which allows more-than-minimal-risk research only when there is a reasonable chance of direct benefits to the child. This means that risk is justified only if the intervention offers a therapeutic benefit that cannot be obtained by other means. Also, the risk must not be disproportionate to the expected benefit and must not exceed the risk of alternative treatments. This section ensures that children are not involved in a study with substantial risk of harm without a likely medical benefit (Yarborough & Sharp, 2009). Together, SS 50.51 and 50.52 create a strict risk-benefit test that protects children from exploitation while allowing access to potential clinical benefits.

Furthermore, according to 21 CFR §56.111, IRBs must review pediatric research proposals to ensure that risks are minimal, subject selection is fair, and consent is suitable. This enhances oversight by requiring independent committees to certify that ethical standards are met before a study begins. The Common Rule (45 CFR 46 Subpart D) is one law that aligns with these regulations and helps prevent children from participating in research projects without proper safeguards (Protection of Human Subjects and Institutional Review Boards, 2022).

Special Considerations in Pediatric Research

Children are not just small adults. They have different motivational needs compared to adults. Children must be motivated in ways that differ from adults. Their physical, cognitive, emotional, and developmental differences mean these factors should be considered in research design. The first is assent and developmental capacity. Children’s ability to understand research varies greatly depending on their age, maturity, and psychological development. For example, adolescents might understand complex information about risks and benefits, while younger children may only grasp a simple explanation. Researchers must also provide age-appropriate information and recognize child dissent. The FDA and ICH E11(R1) guidelines specify that assent is not just the absence of objection but is an actual agreement to participate (FDA, 2018). In longitudinal studies, assent should be revisited as children grow, and full consent must be obtained if the child reaches the age of majority during the study.

The second consideration is outcome and formulation, which should be age-appropriate. Pediatric research must rely on outcome measures relevant to children’s developmental stages, not adult indicators. Conversely, a trial in infants needs to focus on growth, developmental milestones, or symptom relief during early life rather than self-reported results. Similarly, drug formulations should be child-friendly. Dosages need to accommodate small body sizes, and products should avoid dangerous excipients or manipulations (e.g., crushing adult tablets). Taste and palatability are also essential, as inedible drugs can lead to poor adherence and dosing errors. Early planning of pediatric protocols ensures children receive safe, convenient treatments that prevent risky workarounds in clinical practice (21 CFR Part 50 — Protection of Human Subjects, n.d.).

The considerations of both assent and formulation clarify that pediatric research should not be directly copied but only carefully adapted based on studies conducted on adults. Until researchers address these concerns proactively, they will not only treat the child as an equal but also ensure the study is scientifically sound and morally upright.

Ethical Issues and Public Trust

Besides legal implications and specific needs, ethical responsibilities must also be taken into account. Minimizing risk is one of the most important ethical principles. Children should not be enrolled in research unless the question is so crucial to pediatric health that it cannot be answered using existing adult data or animal studies. Justice is an ethical standard that requires research to benefit children reasonably without exposing them to unnecessary burdens (Yarborough & Sharp, 2009).

Public trust and transparency are also crucial. Past disasters like Jesse Gelsinger’s death in a gene therapy trial demonstrate that neglecting conflict of interest management and poor consent procedures can lead to serious consequences. Trust in research can be easily lost if safety and openness are not assured. To address this, researchers should transparently communicate risks to parents and children, manage financial conflicts of interest, and implement strict safety monitoring systems. As Yarborough and Sharp (2009) explain, maintaining trust requires more than just following regulations; individuals must communicate openly, respond to concerns, and be accountable in case of adverse events.

Lastly, fair access is an ethical necessity. Children from different socioeconomic and cultural backgrounds should be included in the study to ensure that findings can be applied to a broader range of populations. Excluding children from underserved populations risks creating disparities in access to new treatments. FDA guidelines specify that research designs must be based on a fair selection of subjects without undue influence on vulnerable families (21 CFR Part 50 — Protection of Human Subjects, n.d.).

Conclusion

Research involving children is vital but ethically challenging. As outlined in 21 CFR 50.51 and 50.52, legal protections secure children by requiring minimal risk or direct clinical benefit, and IRBs must confirm these standards are met. Age-appropriate assent and child-friendly drug formulations emphasize the need to consider developmental differences in study design. Moral principles such as harm reduction, transparency, and fair distribution are essential for maintaining societal trust. Despite these difficulties, pediatric research is key to developing safe and effective treatments for children. Conducted under strict regulatory and ethical standards, pediatric research protects young patients and advances scientific knowledge.

References

21 CFR Part 50 — Protection of human subjects. (n.d.). https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-50

Food and Drug Administration. (2018). E11(R1) addendum: Clinical investigation of medicinal products in the pediatric population. U.S. Department of Health and Human Services.

Protection of human subjects and institutional review boards. (2022, September 28). Federal Register. https://www.federalregister.gov/documents/2022/09/28/2022-21088/protection-of-human-subjects-and-institutional-review-boards

Yarborough, M., & Sharp, R. R. (2009). Public trust and research a decade later: What have we learned since Jesse Gelsinger’s death? Molecular Genetics and Metabolism, 97(1), 4–5. https://doi.org/10.1016/j.ymgme.2009.02.002

HCR 578: Children in Research: Legal Protections and Special Considerations

CLICK HERE TO ORDER A PLAGIARISM-FREE PAPER

HCR 576 Leadership Qualities Needed in the Food Industry

/in /by

HCR 576 Leadership Qualities Needed in the Food Industry

Disruptions in the global food supply chains, changing consumer needs, food safety regulations, sustainability issues, and continuous innovation are some of the challenges that are encountered by the food industry. To cope with these complexities, leaders should possess qualities that can result in organizational success as well as employee satisfaction. According to the research based on the theory of leadership, organizational culture, and the regulatory practices, there are four important qualities, which are:

Collaborative Relationship-Building

Food companies work in large supply chains with farmers, suppliers, regulators, and retailers. Good leaders need to develop teamwork within and outside the organization. According to Leslie and Palmisano (2014), one of the best leadership competencies in dealing with complexity within an industry that relies on partnerships is collaboration.

This is similar to regulatory strategies outlined by the U.S. Food and Drug Administration (FDA), whereby agencies like the Center for Drug Evaluation and Research (CDER) established collaborative units to promote the safety of drugs by facilitating inter-divisional communication (Murphy & Mathieu, 1987). In the food industry, leaders must build trust with suppliers to support sustainable sourcing and work closely with regulatory agencies to maintain compliance. Equally important, they should engage with consumers to strengthen loyalty and sustain long-term brand success (Murphy & Mathieu, 1987). A perfect example is the sourcing of cocoa by Nestlé all over the world, where the company collaborates with farmers, NGOs, and governments to maintain ethical labor standards and sustainability.

Strategic Vision and Perspective

The rapidly evolving consumer preferences, like the need to consume healthier, organic, or vegan food, influence the food industry. Leaders must be able to foresee such changes and rectify the strategies of the company. A strategic vision enables the executives to evaluate complicated issues, predict the market prospects, and take decisive actions (Leslie and Palmisano, 2014).

According to MSEd (2024), contingency leadership theories emphasize the importance of modifying strategies based on the context. Such flexibility is related to the adaptability of FDA advisory committees in their evaluations of evolving circumstances in clinical trials and drug approvals. The move by Heineken to enter the alcohol-free drinks market is an example of how strategic leaders address the trends of health-conscious consumers and align the brand to grow in the long term.

Change-Oriented Leadership

Food companies are constantly changing due to technological changes, sustainability efforts, or regulatory requirements. The ability to change effectively and manage the change allows leaders to not only implement new processes but also mitigate employee resistance (Leslie & Palmisano, 2014).

The theory of transformational leadership underpins this: leaders who communicate a clear vision and inspire employees contribute to flexibility (MSEd, 2024). On the same note, the adoption of electronic technologies, including the Adverse Event Reporting System (AERS) by the FDA in post-marketing monitoring, depicts how organizations can adopt innovations to enhance safety and efficiency. The heads of food industries should demonstrate the same motivation in embracing digital technology in logistics, quality management, or marketing to consumers (MSEd, 2024). The case of Hershey shifting to digital marketing and e-commerce shows how executives can facilitate cultural transformation in traditional companies.

People-Centered Leadership and Cultural Alignment

The food industry has diverse workforces in the manufacturing sector, logistics, and marketing. As Tsai (2011) stresses, leadership behavior has a significant impact on employee job satisfaction and the organizational culture. Leaders who help employees, offer vision, and match the action to organizational values build motivated and engaged teams.

The regulatory model of the FDA demonstrates the role of regular communication, the principle of transparency, and ethical responsibility in enhancing the credibility of regulatory decisions. On the same note, food industry leaders should ensure that employees feel appreciated by offering them opportunities for professional growth, inclusion, and a sense of sustainability (Murphy & Mathieu, 1987). At Coors, for example, leaders who highlight safety, diversity, and career growth foster loyalty and performance across teams.

Conclusion

Leaders in the food industry excel when they build strong working relationships, offer strategic vision, manage change effectively, and foster inclusive cultures. Experiences with regulatory bodies, such as the FDA, including post-marketing reviews and advisory committee structures, demonstrate that flexibility, teamwork, and open management help strengthen organizational resilience. The ability to combine strategic vision with people-focused leadership enables food industry leaders to navigate complex global markets while staying compliant with regulations. At the same time, it allows them to motivate employees and respond to evolving consumer needs efficiently.

References

Leslie, J., & Palmisano, K. (2014). The leadership challenge in the pharmaceutical sector: What critical capabilities are missing when it comes to leadership talent, and how can they be developed? https://doi.org/10.35613/ccl.2014.1064

MSEd, K. C. (2024, July 15). The major leadership theories. Verywell Mind. https://www.verywellmind.com/leadership-theories-2795323

Murphy, W. J., & Mathieu, M. P. (1987). New drug development: a regulatory overview.

Tsai, Y. (2011). Relationship between Organizational Culture, Leadership Behavior, and Job Satisfaction. BMC Health Services Research, 11(1). https://doi.org/10.1186/1472-6963-11-98

HCR 576 Leadership Qualities Needed in the Food Industry

CLICK HERE TO ORDER A PLAGIARISM-FREE PAPER